...
首页> 外文期刊>Scientific reports. >Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine
【24h】

Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine

机译:将病毒样粒子作为PFS47靶向疟疾传输疫苗的抗原平台

获取原文
   

获取外文期刊封面封底 >>

       

摘要

We recently characterized Pfs47, a protein expressed on the surface of sexual stages and ookinetes of Plasmodium falciparum, as a malaria transmission-blocking vaccine (TBV) target. Mice immunization induced antibodies that conferred strong transmission-reducing activity (TRA) at a concentration of 200?μg/mL. Here, we sought to optimize the Pfs47 vaccine to elicit higher titers of high-affinity antibodies, capable of inducing strong TRA at a lower concentration. We report the development and evaluation of a Pfs47-based virus-like particle (VLP) vaccine generated by conjugating our 58 amino acid Pfs47 antigen to Acinetobacter phage AP205-VLP using the SpyCatcher:SpyTag adaptor system. AP205-Pfs47 complexes (VLP-P47) formed particles of ~22?nm diameter that reacted with polyclonal anti-Pfs47 antibodies, indicating that the antigen was accessible on the surface of the particle. Mice immunized with VLP-P47 followed by a boost with Pfs47 monomer induced significantly higher antibody titers, with higher binding affinity to Pfs47, than mice that received two immunizations with either VLP-P47 (VLP-P47/VLP-P47) or the Pfs47 monomer (P47/P47). Purified IgG from VLP-P47/P47 mice had strong TRA (83-98%) at concentrations as low as 5?μg/mL. These results indicate that conjugating the Pfs47 antigen to AP205-VLP significantly enhanced antigenicity and confirm the potential of Pfs47 as a TBV candidate.
机译:我们最近表征了PFS47,一种在性阶段表面表达的蛋白质和疟原虫疟原虫的oOkinetes,作为疟疾传输阻断疫苗(TBV)靶标。小鼠免疫诱导抗体,其赋予强大的传递 - 还原活性(TRA),其浓度为200μg/ ml。在这里,我们寻求优化PFS47疫苗以引发高亲和力抗体的更高滴度,能够以较低浓度诱导强TRA。我们报告了通过使用Spycatcher:SpyTag适配器系统将我们的58个氨基酸PFS47抗原缀合到传导噬菌体AP205-VLP的PFS47的病毒样颗粒(VLP)疫苗的开发和评估。 AP205-PFS47复合物(VLP-P47)形成〜22Ω·NM直径的颗粒,其与多克隆抗PFS47抗体反应,表明抗原可在颗粒的表面上接近。用VLP-P47免疫的小鼠,然后用PFS47单体诱导显着更高的抗体滴度,其对PFS47具有更高的结合亲和力,而不是与VLP-P47(VLP-P47 / VLP-P47)或PFS47单体接受两个免疫的小鼠(p47 / p47)。来自VLP-P47 / P47小鼠的纯化IgG在低至5μg/ mL的浓度下具有强TRA(83-98%)。这些结果表明,将PFS47抗原与AP205-VLP缀合显着增强的抗原性,并确认PFS47作为TBV候选的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号